2016
DOI: 10.3892/ol.2016.4111
|View full text |Cite
|
Sign up to set email alerts
|

A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type

Abstract: Due to frequent phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway dysregulation, AKT is typically accepted as a promising anticancer therapeutic target. mTOR, in particular, represents a suitable therapeutic target for hepatocellular carcinoma, whilst suppressor with morphogenetic effect on genitalia family member-1 (SMG-1) is believed to serve a potential tumor suppressor role in human cancer. Despite SMG-1 and mTOR belonging to the same PI3K-related kinase family, th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
19
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(21 citation statements)
references
References 42 publications
2
19
0
Order By: Relevance
“…We chose to test the effects of two AKT inhibitors, AZD5363 (AZD) and MK2206-HCl (MK), on synaptic plasticity. AZD and MK have different mechanisms of action; AZD is an ATP-competitive AKT inhibitor ( Zhang et al, 2016 ) and MK is an allosteric AKT inhibitor ( Liu et al, 2011 ). To examine AZD and MK action in the brain, we first assessed their effects on the phosphorylation of AKT and a well-characterized downstream target of AKT, glycogen synthase kinase 3β (GSK-3β) in hippocampal slices.…”
Section: Resultsmentioning
confidence: 99%
“…We chose to test the effects of two AKT inhibitors, AZD5363 (AZD) and MK2206-HCl (MK), on synaptic plasticity. AZD and MK have different mechanisms of action; AZD is an ATP-competitive AKT inhibitor ( Zhang et al, 2016 ) and MK is an allosteric AKT inhibitor ( Liu et al, 2011 ). To examine AZD and MK action in the brain, we first assessed their effects on the phosphorylation of AKT and a well-characterized downstream target of AKT, glycogen synthase kinase 3β (GSK-3β) in hippocampal slices.…”
Section: Resultsmentioning
confidence: 99%
“…The PI3K/Akt/mTOR signalling pathway is important for cell proliferation. However, due to its frequent dysregulation, Akt is typically accepted as a promising anticancer therapeutic target ( 17 ). This signalling pathway is activated by various extracellular growth factors, including epidermal growth factor, insulin-like growth factor 1 and insulin, and simulates downstream mTOR signalling ( 18 ).…”
Section: Resultsmentioning
confidence: 99%
“…We chose to test the effects of two AKT inhibitors, AZD5363 (AZD) and MK2206-HCl (MK), on synaptic plasticity. AZD and MK have different mechanisms of action; AZD is an ATP-competitive AKT inhibitor 17 and MK is an allosteric AKT inhibitor 18 . To examine AZD and MK action in the brain, we first assessed their effects on the phosphorylation of AKT and a well-characterized downstream target of AKT, glycogen synthase kinase 3β (GSK-3β) in hippocampal slices.…”
Section: Resultsmentioning
confidence: 99%